

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification at page 3, first paragraph as follows:

The present invention provides a new stable pharmaceutical composition comprising EPO, a pharmaceutically acceptable pH buffering system, and polyvinylpyrrolidone (PVP). ~~in accordance with claim 1. Preferred embodiments are set forth in the sub-claims.~~ The present invention also provides a use of PVP for the stabilization of erythropoietin (EPO) in an aqueous solution according to claim 17, a process for preparing a composition containing erythropoietin (EPO), comprising mixing EPO with PVP according to claim 18, and a use of a composition comprising EPO, a pharmaceutically acceptable pH buffering system, and polyvinylpyrrolidone (PVP for the treatment and/or prevention of diseases indicated for erythropoietin (EPO) according to claim 20.